Antibiotic resistance: Federal agencies have taken steps to combat the threat, but additional actions needed : testimony before the Subcommittee on Oversight and Investigations, Committee on Energy and Commerce, House of Representatives

Antibiotic resistance: Federal agencies have taken steps to combat the threat, but additional actions needed : testimony before the Subcommittee on Oversight and Investigations, Committee on Energy and Commerce, House of Representatives

Collection:
Health Policy and Services Research
Alternate Title(s):
Federal agencies have taken steps to combat the threat, but additional actions needed: testimony before the Subcommittee on Oversight and Investigations, Committee on Energy and Commerce, House of Representatives
Contributor(s):
United States. Government Accountability Office, issuing body.
United States. Congress. House. Committee on Energy and Commerce. Subcommittee on Oversight and Investigations, addressee.
Publication:
Washington, DC : United States Government Accountability Office, April 28, 2023
Language(s):
English
Format:
Text
Subject(s):
Drug Resistance, Microbial
Government Regulation
Legislation, Medical
United States
United States. Department of Health and Human Services
Genre(s):
Technical Report
Abstract:
Why GAO did this study. Concerns about rising rates of antibiotic resistance prompted the federal government to create the National Action Plan for Combating Antibiotic-Resistant Bacteria in 2015 and again in 2020. The plan called for federal agencies to strengthen surveillance, advance the development of diagnostic tests and new antibiotics, and slow the emergence of resistant bacteria, among other things. This testimony summarizes GAO’s March 2020 report on federal efforts and challenges related to (1) surveillance of antibiotic resistance, (2) diagnostic testing to identify resistant infections, and (3) the development of treatments for resistant infections, among others. This testimony also highlights the recommendations GAO made in that report and includes information on agency progress toward implementing them. For that report, GAO reviewed literature and agency documents; interviewed agency officials and health care industry, drug industry, and other stakeholders; and held a meeting of international and U.S. experts to obtain their views. What GAO recommends. GAO made eight recommendations in its March 2020 report. HHS concurred with seven of the recommendations in 2020. It did not concur with the recommendation for a strategy on incentives. However, it has begun taking steps to implement this recommendation and another five. HHS has not taken significant steps on the two remaining recommendations. GAO will continue to monitor HHS’s progress.
Copyright:
The National Library of Medicine believes this item to be in the public domain. (More information)
Extent:
1 online resource (1 PDF file (13 pages))
Illustrations:
Illustrations
NLM Unique ID:
9918627771506676 (See catalog record)
Permanent Link:
http://resource.nlm.nih.gov/9918627771506676